Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
暂无分享,去创建一个
M. Chonchol | S. Fishbane | P. Pergola | M. Davidson | V. Mathur | R. Kakkar | L. Lo | M. Devalaraja | Mark T. Smith | Kurt Herzog | Larry Lo | Vandana S. Mathur
[1] M. Davidson,et al. Abstract 13727: Effects of Ziltivekimab (ZILTI), a Novel Anti-Interleukin-6 Monoclonal Antibody, on Markers of Inflammation and Cardiovascular Risk in Patients With Chronic Kidney Disease on Hemodialysis , 2019 .
[2] G. Latunde-Dada,et al. Anemia of Inflammation with An Emphasis on Chronic Kidney Disease , 2019, Nutrients.
[3] T. Assanasen,et al. Factors associated with erythropoiesis-stimulating agent hyporesponsiveness anemia in chronic kidney disease patients , 2019, Hematology reports.
[4] T. Ganz. Anemia of Inflammation. , 2019, The New England journal of medicine.
[5] T. Kuragano,et al. ESA Hyporesponsiveness Is Associated with Adverse Events in Maintenance Hemodialysis (MHD) Patients, But Not with Iron Storage , 2016, PloS one.
[6] G. Yancopoulos,et al. Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN) , 2014, Annals of the rheumatic diseases.
[7] L. De Nicola,et al. Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[8] Michela Traglia,et al. TMPRSS6 rs855791 modulates hepcidin transcription in vitro and serum hepcidin levels in normal individuals. , 2011, Blood.
[9] R. Bigazzi,et al. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[10] Z. Massy,et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. , 2010, Kidney international.
[11] S. Solomon,et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. , 2009, The New England journal of medicine.
[12] Gonçalo Abecasis,et al. Genome-wide association study identifies variants in TMPRSS6 associated with hemoglobin levels , 2009, Nature Genetics.
[13] T. Ganz,et al. Iron sequestration and anemia of inflammation. , 2009, Seminars in hematology.
[14] T. Eleftheriadis,et al. The Role of Hepcidin in Iron Homeostasis and Anemia in Hemodialysis Patients , 2009, Seminars in dialysis.
[15] B. Braam,et al. Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure , 2008, Nature Clinical Practice Nephrology.
[16] Ajay K. Singh,et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. , 2007, Journal of the American Society of Nephrology : JASN.
[17] Huiman Barnhart,et al. Correction of anemia with epoetin alfa in chronic kidney disease. , 2006, The New England journal of medicine.
[18] T. Eleftheriadis,et al. Does Hepcidin Affect Erythropoiesis in Hemodialysis Patients? , 2006, Acta Haematologica.
[19] N. Andrews,et al. Interleukin-6 induces hepcidin expression through STAT3. , 2006, Blood.
[20] J. Shapiro,et al. HEMATOLOGY: ISSUES IN THE DIALYSIS PATIENT: Erythropoietin Resistance in the Treatment of the Anemia of Chronic Renal Failure , 2006, Seminars in dialysis.
[21] P. Bárány,et al. Inflammation and resistance to erythropoiesis-stimulating agents--what do we know and what needs to be clarified? , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[22] B. Jaber,et al. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[23] Grace H. Lee,et al. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[24] P. Stenvinkel,et al. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[25] S. Fishbane,et al. The evaluation of iron status in hemodialysis patients. , 1996, Journal of the American Society of Nephrology : JASN.
[26] A. R. Jonckheere,et al. A DISTRIBUTION-FREE k-SAMPLE TEST AGAINST ORDERED ALTERNATIVES , 1954 .
[27] T. J. Terpstra,et al. The asymptotic normality and consistency of kendall's test against trend, when ties are present in one ranking , 1952 .